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Activating mutations in the FLT3 receptor tyrosine kinase occur in 30% of patients with acute myeloid leukemia. Small mole-
cule FLT3 kinase inhibitors show selective antitumor activity in preclinical models. Clinical studies are underway.
The remarkable success of the small molecule tyrosine kinase
inhibitor STI571 (also called Gleevec or imatinib) has galva-
nized the cancer research community to hasten the pursuit of
new molecularly targeted therapy. Voices of caution warn that
STI571 may be a one-time example because of the unique
molecular features of chronic myeloid leukemia (CML) that
make it the perfect candidate for single agent targeted therapy.
CML results from the action of the BCR-ABL tyrosine kinase,
created by the Philadelphia chromosome translocation. BCR-
ABL is sufficient to cause leukemia in mouse models, but addi-
tional genetic hits occur over time as the disease progresses to
the terminal phase called blast crisis (Sawyers, 1999). STI571
blocks BCR-ABL kinase activity and induces remissions in
nearly all patients in the early stages of the disease, providing
the best validation to date of the concept of molecularly targeted
cancer therapy (Druker et al., 2001b; Kantarjian et al., 2002). In
late stage CML, STI571 remains effective in a large fraction of
patients (Druker et al., 2001a; Sawyers et al., 2002; Talpaz et
al., 2002), but remissions are short-lived due to drug resistance
that develops as a consequence of BCR-ABL kinase domain
mutation or gene amplification (Branford et al., 2002; Gorre et
al., 2001; von Bubnoff et al., 2002). The fact that STI571 is less
effective in blast crisis CML, together with the lower response
rates observed with other kinase inhibitors in solid tumors, has
led to skepticism about whether this approach can be success-
fully extended to other cancers.
Soon we will have data from four new kinase inhibitors that
speak to this question in acute myeloid leukemia (AML). Two
papers in the current issue of Cancer Cell and a recent paper in
Blood report promising preclinical results with three different
inhibitors of the tyrosine kinase receptor FLT3, a therapeutic tar-
get in AML (Kelly et al., 2002c; Weisberg et al., 2002; Levis et
al., 2002). Comparable results have been reported in abstract
form for a fourth FLT3 inhibitor (O’Farrell et al., 2001). All four
compounds are currently in clinical testing, with preliminary
results expected in 6–12 months. Since AML is a hematologic
malignancy characterized by multiple oncogenic hits (unlike
CML), successful results with any of these new compounds
would make a compelling case for the power of targeted molec-
ular therapy in genetically complex cancers.
Rationale for targeting FLT3 in AML
Approximately one-third of patients with AML have mutations in
FLT3 that lead to constitutive activation of the kinase as well as
downstream signaling pathways (Nakao et al., 1996; Hayakawa
et al., 2000; Kiyoi et al., 1999). Unlike BCR-ABL, which is acti-
vated by gene fusion due to the Philadelphia chromosome
translocation, FLT3 activation in AML typically occurs due to
internal tandem duplications in the kinase insert domain. An
alternative mechanism is point mutation in the activation loop of
the kinase (Yamamoto et al., 2001). The mutant FLT3 receptor
causes cellular transformation and produces a myeloprolifera-
tive syndrome in mice (Kelly et al., 2002b), much like BCR-ABL
(Daley et al., 1990).The fact that mutant FLT3 is not sufficient to
cause full-blown AML supports a two-hit model for the genesis
of acute leukemia. Experimental evidence suggests that an acti-
vated tyrosine kinase (which induces myeloid proliferation) must
be paired with a second mutation affecting hematopoietic differ-
entiation (such as a transcription factor translocation) to give the
full disease phenotype (Kelly et al., 2002a).
Why do we suddenly have four different inhibitors against
the same kinase target? A review of the chemical structures
and specificity profiles of these inhibitors provides some insight
(Table 1). CEP-701 is an indolocarbazole derivative, originally
reported to inhibit the TrkA receptor tyrosine kinase (George et
al., 1999), and now shown to inhibit FLT3 (Levis et al., 2002).
PKC412 is staurosporine derivative with activity against FLT3,
as well as protein kinase C, KDR (also called VEGFR2 or FLT1),
PDGFR, c-Kit, and FMS (Fabbro et al., 1999; Weisberg et al.,
2002). SU11248, whose precise chemical structure has not
been published, is an indolinone-based inhibitor of KDR, c-kit,
and FLT3, similar to the less potent parent compound SU5416
(Fong et al., 1999; O’Farrell et al., 2001). Finally, CT53518 is a
novel compound of the piperazinyl quinazoline class with activi-
ty against PDGFR, c-kit, and FLT3—a specificity profile similar
to SU11248 despite quite distinct chemical structures (Kelly et
al., 2002c).
All four compounds are postulated to function as ATP bind-
ing site inhibitors. How, then, can they all block ATP binding to
FLT3, yet retain such distinct chemical structures and specificity
profiles? Knowing the answer requires solving crystal structures
of each inhibitor bound to the FLT3 kinase domain, but we can
make educated guesses based on other kinase/inhibitor
cocrystals. Kinase domains are dynamic structures which move
from active to inactive conformations and undergo dramatic
shape changes during these transitions (Huse and Kuriyan,
2002). Structurally different inhibitors can bind to the same
kinase domain by taking advantage of these shape changes.
For example, STI571 binds to Abl when the kinase domain is in
the “off” configuration and locks it in an inactive state (Schindler
et al., 2000), whereas, a second Abl inhibitor, PD 173955, binds
Abl in the “on” configuration (J. Kuriyan, personal communica-
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tion). This distinction provides a compelling explanation for the
fact that PD 173955 is a potent inhibitor of both Abl and Src,
whereas STI571 only inhibits Abl. The assumption, then, is that
the active conformations of Src and Abl are structurally similar
(allowing equivalent binding of PD 173955), whereas the inac-
tive conformations are not (providing specificity for STI571).
Similar logic applied to the four FLT3 inhibitors predicts that
each might bind FLT3 in slightly different transition states
between the active and inactive conformations of the kinase
domain. The relative similarity of these transition states to those
of other kinases in Table 1, such as KDR, PDGFR, and c-kit
might explain the differences in crossreactivity.
Choosing the optimal clinical development strategy
With four FLT3 inhibitors racing into the clinic, is it possible to
predict the winner? One concern frequently voiced during the
clinical planning stages of kinase inhibitors is toxicity, particular-
ly if the compound has broad activity. Intuition would tell us that
clinical success is more likely if an inhibitor is highly specific.
The compounds in Table 1 show clear differences here that may
impact safety and tolerability. But we should learn from the
STI571 experience. The STI571 dose used in CML (for BCR-
ABL inhibition) also blocks wild-type Abl, c-kit, and PDGFR.Yet
the drug is extremely well tolerated in animals and patients—
despite the fact that knockout mice lacking either Abl, Kit, or
PDGFR all have severe phenotypes.Traditional toxicology stud-
ies are still the best guide for preclinical safety evaluation, and
we should not rule out a possible drug solely on the basis of the
kinase inhibition profile.
What is the best clinical trial design? The preclinical data for
all four compounds argues that AML patients whose leukemia
cells have FLT3 mutations should respond. All compounds
showed selective activity against cell lines and murine leukemia
models engineered to express mutant FLT3 (Kelly et al., 2002c;
Levis et al., 2002; Weisberg et al., 2002). One group also
demonstrated a correlation between presence of FLT3 mutation
and antileukemia activity by studying AML patient material cul-
tured in vitro (Levis et al., 2002; Levis et al., 2001). A potential
problem with the logic of testing these drugs only in AML
patients with FLT3 mutation is that FLT3 may not be the true tar-
get of these inhibitors. While there is very little evidence to sup-
port this contention, it is curious that the inhibitor with the broad-
est activity (PKC412) shows a discrepancy between inhibition
of purified FLT3 kinase domain in vitro (IC50 = 528 nM) and inhi-
bition of endogenous FLT3 in cells (IC50 < 10 nM) (Weisberg et
al., 2002). Although differences between in vitro and cellular
IC50s are common with kinase inhibitors, the trend is typically in
the opposite direction and is usually explained by issues involv-
ing transport across the cell membrane. The PKC412 discrep-
ancy might be technical, since the in vitro assay uses the wild-
type FLT3 kinase domain rather than mutant FLT3. However, it
remains formally possible that the target for this compound is
another kinase closely associated with FLT3. The authors
addressed this issue by deriving PKC412-resistant cell lines,
and observed amplification of the FLT3 transgene (Weisberg et
al., 2002). This result provides strong evidence that FLT3 is the
true target, but the most convincing proof would come from iso-
lating a PKC412-resistant FLT3 mutant, analogous to BCR-ABL
mutants that confer STI571 resistance (Gorre et al., 2001; von
Bubnoff et al., 2002). Assuming that FLT3 is the relevant drug
target in these models, we must still decide if enrollment to clin-
ical trials should be restricted to AML patients with FLT3 muta-
tions. My personal bias would be to restrict enrollment in the ini-
tial trials so that the experimental hypothesis is tested cleanly
and efficiently. I believe this approach affords the best chance of
a clinical result that will generate excitement in the cancer com-
munity, which will lead to rapid patient accrual to the large regis-
tration trials required for FDA approval. But a word of caution is
in order, since clinical responses have already been observed
in AML patients in the phase I studies of SU5416, the precursor
molecule to SU11248 (Yee et al., 2001). It is not known if these
patients had FLT3 abnormalities; therefore, it remains possible
that inhibition of other SU5416 targets, such as KDR or c-Kit,
could explain the clinical responses.
With all four compounds entering the clinic simultaneously,
it is interesting to speculate on the potential outcomes. Safety
and tolerability are essential benchmarks that are impossible to
predict in advance, and proper dose selection for achieving
blood levels that give sustained FLT3 inhibition in tumor cells
requires careful pharmacokinetic and pharmacodynamic
Table 1. Inhibitory activity (IC50) of FLT3 kinase inhibitors against a panel of tyrosine kinase targets (all values are nM)
Drug
Kinase CEP-701 CT 53518 PKC412 SU11248 SU5416a
FLT3 3 (iv) 220 (iv) 528 (iv); <10 (c) 10 (c) 250 (c)
PKC 218 (iv) >30,000 (c) 22 (iv)  
KDR 65 (iv) >30,000 (c) 86 (iv) 10 (c) 1230 (iv)
PDGFR 773 (iv) 200 (iv) 80 (c) 10 (c) 20,000 (c)
KIT  170 (iv) 300 (c)  
FMS  3430 (iv) *  
TRKA 3.7 (iv)    
EGFR >1,000 (iv) >30,000 (c) >100,000 (iv)  >100,000 (iv)
ABL  >30,000 (iv) 800 (iv)  
SRC  >30,000 (iv) >100,000 (iv)  
IC50 = concentration of drug required to achieve 50% inhibition; iv = IC50 as measured using an in vitro kinase assay with purified kinase domain; c = IC50 as
measured in cells expressing the kinase.  indicates data not available. Values in this table were obtained from the following references: George et al.,
1999; Fabbro et al., 1999; Levis et al., 2002; Kelly et al., 2002c; O'Farrell et al., 2001; Fong et al., 1999; Weisberg et al., 2002.
aSU5416 is the parent compound for SU11248. 
*Reported to be sensitive; precise IC50 not reported. 
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assessment. In this regard, PKC412 may have a head start
since phase I clinical testing has been completed in patients
with solid tumors (targeting PKC), and favorable safety and
pharmacokinetic data were obtained that predict for successful
FLT3 inhibition (Propper et al., 2001). Assuming that sustained
FLT3 inhibition can be achieved in tumor cells, what type of clin-
ical results can we expect? Because of the phenotypic similari-
ties between AML and blast crisis CML, we might consider the
STI571 experience in myeloid blast crisis as a guide. Response
rates in phase I–II trials were 50–60 percent, with complete remis-
sions in 10–20 percent of cases, but relapses were common
(Druker et al., 2001a; Sawyers et al., 2002). If all four com-
pounds meet the milestone of FLT3 inhibition in tumor cells with
acceptable toxicity, it is unlikely that there will be any losers in
the group. Extrapolating from the STI571 experience, we can
anticipate that resistance to single agent therapy will occur, pre-
sumably through kinase domain mutations or gene amplifica-
tion. How wonderful it would be to have four structurally distinct
FLT3 inhibitors, so that combination therapy against the same
target could be tested as a strategy to block the emergence of
resistance, much like current HIV treatment regimens.
Buried amongst the optimism that STI571 has generated for
targeted cancer therapy are the economic forces at large phar-
maceutical companies that make it difficult to develop drugs for
diseases with small market potential like CML. While AML is
more common than CML, marketing departments must be
aware that FLT3 inhibitors may only be effective in AML patients
with FLT3 mutations (30 percent of all cases). Has there been a
change in the traditional “big pharma” business model to allow
pursuit of such niche markets? We can only guess. Early deci-
sions behind the development of PKC412 and SU11248 were
presumably based on large market potential, since their original
targets (PKC and KDR, respectively) are widely implicated in
cancer. FLT3 offers the advantage of a much better validated
target, presumably at low additional cost for a potentially high
payoff. Whatever the reasons underlying the decisions to go for-
ward, the impact on future business models for cancer drug
development could be substantial if any of these drugs are
financial successes. We all envision the day when oncologists
will select from a wide array of nontoxic, molecularly targeted
therapies based on the molecular phenotype of the tumor. The
ongoing FLT3 clinical trials provide a powerful series of experi-
ments that will teach us a great deal about the science (and the
business) of developing kinase inhibitors for cancer. We should
have some answers soon.
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